Phase I Trial of Vandetanib and Bevacizumab Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumours and Lymphomas

PURPOSE: Inhibition of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) pathways may result in synergistic antitumour activity. We designed a phase I study to evaluate the combination of vandetanib, an investigational agent with activity against EGF receptor and VEGF recep...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kummar, Shivaani, Gutierrez, Martin E., Chen, Alice, Turkbey, Ismail B., Allen, Deborah, Horneffer, Yvonne R., Juwara, Lamin, Cao, Liang, Yu, Yunkai, Kim, Yeong Sang, Trepel, Jane, Chen, Helen, Choyke, Peter, Melillo, Giovanni, Murgo, Anthony J., Collins, Jerry, Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3071434/
https://ncbi.nlm.nih.gov/pubmed/21247755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2010.12.016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados